Skip to content

Study · Not a test of the peptide alone · 2009

1 result

Partial restoration of GH responsiveness to ghrelin in Cushing's disease after 6 months of ketoconazole treatment: comparison with GHRP-6 and GHRH.

Correa-Silva SR, Nascif SO, Molica P, Sá LB, Vieira JG, Lengyel AM

European journal of endocrinology20 Aug 2009Cited by 1 (Europe PMC)

PMID19696160 (opens in a new tab)DOI10.1530/eje-09-0459 (opens in a new tab)PepBankPUB-19696160
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, GH release after GHRP‑6 increased after ketoconazole treatment, but not significantly.

    In plain wordsIn people with Cushing's disease, the growth hormone response to GHRP‑6 rose after ketoconazole treatment, but the rise was not significant.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH release after GHRP-6 before and after ketoconazole
    Study

    n = 8

    Comparator
    Before ketoconazole
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GH release after GHRP-6 increased, although not significantly, while GH responsiveness to GHRH was unchanged.
    1 context sentence
    Summary · context
    GH responses to ghrelin, GHRP-6, and GHRH of eight untreated patients with CD (mean age: 33.8+/-3.1 years; body mass index: 28.5+/-0.8 kg/m(2)) were evaluated before and after 3 and 6 months of ketoconazole treatment, and compared with 11 controls (32.1+/-2.5; 25.0+/-0.8).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.